絞り込み

16525

広告

「elotuzumab」の検索結果

192件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.

[Multiple myeloma: update on pathophysiology and management].

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

A look at treatment strategies for relapsed multiple myeloma.

Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Current use of monoclonal antibodies in the treatment of multiple myeloma.

[The most recent developments in diagnosis and treatment of multiple myeloma].

Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.

Elotuzumab-induced interstitial lung disease: the first case report.

Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.

Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.

The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります